O'Brien Institute in analysis deal with UK biotech
04 June, 2002 by Tanya HollisA $1 million deal to analyse molecular changes in tumours has been signed between Melbourne's Bernard O'Brien Institute of Microsurgery (BOBIM) and a private London biotech.
HPLC market report: Cents and sensitivity
04 June, 2002 by Melissa TrudingerEase of use, reliability and service and support are the main things that scientists consider when buying a new chromatography system. But previous familiarity with a particular brand is also a major factor.
Billionare buys Amrad stake
04 June, 2002 by Tanya HollisIn a much-needed show of investor support, cardboard king Richard Pratt has become a substantial shareholder of Amrad Corporation.
New Zealand joins synchrotron project
03 June, 2002 by Tanya HollisA New Zealand representative is to join the Australian Synchrotron Project's scientific advisory committee, cementing a trans-Tasman link between users of the new facility.
CEO, directors depart as Bio21 changes direction
03 June, 2002 by Tanya HollisThe chief executive officer and three other directors have resigned from Bio21 following a restructure that has seen the company abandon its commercial focus.
Signs of new life at Vita Life
31 May, 2002 by Tanya HollisTroubled biopharmaceutical group Vita Life Sciences has warned shareholders not to expect much from the natural medicines arm of its business in the coming year.
Academy admits ARC head Sara
31 May, 2002 by Daniella GoldbergAustralian Research Council CEO Prof Vicki Sara has been admitted by special election as a fellow of the Australian Academy of Science, for her contribution to recent government reforms and initiatives.
Biotech stocks will keep falling... but not too far
30 May, 2002 by Daniella GoldbergAustralian biotechnology companies may be heading for a further tumble, delegates at the Financing Biotechnology meeting in Sydney this week were told.
Prana aims for Nasdaq
29 May, 2002 by Pete YoungPrana Biotechnology is following up recent successful Phase II clinical trials of its therapy for age-related diseases such as Alzheimer's with a bid to list on the US Nasdaq.
Premier makes a cautious ASX debut
29 May, 2002 by Tanya HollisPremier Bionics made a quiet entry to a cautious biotech market today when it listed on the Australian Stock Exchange.
ACT feature: The small territory with big ideas
29 May, 2002 by Melissa TrudingerThe Australian Capital Territory (ACT) has two big advantages when it comes to biotechnology: world-class scientists and its proximity to the Federal government.
WA feature: Miners digging for biotech
28 May, 2002 by Pete YoungBiotech companies and WA's bedrock industry - mining - appear to have little in common.
WA feature: Could biotech be the west's next gold rush?
28 May, 2002 by Pete YoungWestern Australia's bio-industry faces more than its share of hurdles. It is isolated by geography, limited by population and dependent on a State government focussed on traditional resources and agriculture sectors.
Eleventh hour resolution for Amrad
28 May, 2002 by Tanya HollisAn air of disappointment hung over the handful of Amrad shareholders who turned up to what was supposed to be an extraordinary general meeting on May 22.
IDT buys clinical trials research unit
27 May, 2002 by Tanya HollisContract research group Institute of Drug Technology Australia (ASX: IDT) has purchased a clinical trials research unit in a deal the company said will bolster its annual revenue by 20 per cent.
